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ABSTRACT 22
Basal gene expression levels have been shown to be predictive of cellular response to cytotoxic 23 treatments. However, such analyses do not fully reveal complex genotype-phenotype 24 relationships, which are partly encoded in highly interconnected molecular networks. Biological 25 pathways provide a complementary way of understanding drug response variation among 26 individuals. In this study, we integrate chemosensitivity data from a recent pharmacogenomics 27 study with basal gene expression data from the CCLE project and prior knowledge of molecular 28 networks to identify specific pathways mediating chemical response. We first develop a 29 computational method called PACER, which ranks pathways for enrichment in a given set of 30 genes using a novel network embedding method. It examines known relationships among 31 genes as encoded in a molecular network along with gene memberships of all pathways to 32 determine a vector representation of each gene and pathway in the same low-dimensional 33 vector space. The relevance of a pathway to the given gene set is then captured by the 34 similarity between the pathway vector and gene vectors. To apply this approach to 35 chemosensitivity data, we identify genes with basal expression levels in a panel of cell lines that 36 are correlated with cytotoxic response to a compound, and then rank pathways for relevance to 37 these response-correlated genes using PACER. While significant efforts have focused on specific genes that interact with compounds and confer 75 observed cellular phenotypes, there has been relatively little progress in studying the synergistic 76 effects of genes. These effects are key factors in comprehensively deciphering the mechanisms 77 of action of compounds and understanding complex phenotypes 9 . Similarly, pathways, which 78 comprise a set of interacting genes, have emerged as a useful construct for gaining insights into 79 cellular responses to compounds. Analysis at the pathway level not only reduces the analytic 80 complexity from tens of thousands of genes to just hundreds of pathways, but also contains 81 more explanatory power than a simple list of differentially expressed genes 10 . Consequently, an 82 important yet unsolved problem is the effective identification of pathways mediating drug 83 response variation. Although the associated pathways for certain drugs have been studied 84 experimentally [11] [12] [13] , in vitro pathway analysis is costly and inherently difficult, making it hard to 85 scale to hundreds of compounds. 86 87
Fortunately, a growing compendium of genomic, proteomic, and pharmacologic data allows us 88 to develop scalable computational approaches to help solve this problem. Although statistical 89 significance tests and enrichment analyses can be naturally applied to compound-pathway 90 association identification (e.g., by testing the overlap between pathway members and 91 differentially expressed genes), these approaches fail to leverage well-established biological 92 relationships among genes [14] [15] [16] [17] . Even when analyzing individual genes, molecular networks 93 such as protein-protein interaction networks have been shown to play crucial roles in 94 understanding the cellular drug response 9, [18] [19] [20] [21] . Therefore, we propose to combine similar 95 molecular networks with gene expression and drug response data for pathway identification. 96
However, integrating these heterogeneous data sources is statistically challenging. Moreover, 97 networks are high-dimensional, incomplete, and noisy. Thus, our algorithm needs to accurately 98 and comprehensively identify pathway while exploiting suboptimal networks. 99 100
In this work, we present PACER, a novel, network-assisted algorithm that identifies pathway 101 associations for any gene set of interest. Additionally, we apply the algorithm to discover 102 chemosensitivity-related pathways. PACER first constructs a heterogeneous network that 103 includes pathways and genes, pathway membership information, and gene-gene relationships 104 from a molecular network such as protein-protein interaction network. It then applies a novel 105 dimensionality reduction algorithm to this heterogeneous network to obtain compact, low-106 dimensional vectors for pathways and genes in the network. Pathways that are topologically 107 close to drug response-related genes in the network are co-localized with those genes in this 108 low-dimensional vector space. Hence, PACER ranks each pathway based on its proximity in the 109 low-dimensional space to genes that have basal expressions highly correlated with drug 110 response. We evaluated PACER's ability to identify compound-pathway associations with three 111 'ground truth' sets built from compound target data 8 , compound structure data 22 , and LINCS 112 differential expression data 23 . When comparing PACER to state-of-the-art methods that ignore 113 prior knowledge of interactions among genes, we observed substantial improvement of the 114 concordance with the chosen benchmarks. Even though we developed PACER and tested its 115 ability to identify compound-pathway associations, the algorithm is applicable to any scenario in 116 which one seeks to discover pathways related to a pre-specified gene set of interest, while 117 utilizing a given gene network .  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146 
MATERIALS AND METHODS 147
Compound response data and gene expression data 148
We obtained a large-scale compound response screening dataset from Rees et al. 8 Figure 1A ). Compared to the IC50 and EC50 scores, AUC simultaneously captures the 233 efficacy and potency of a drug. Of the ~8.7 million pairs of genes and compounds tested, we 234 found 294,789 to be significantly correlated (p-value < 0.0001 after Bonferroni correction, 235 corresponding to a Pearson correlation coefficient of 0.215). Within these significantly correlated 236 pairs, 1,749 genes were correlated with over 100 compounds ( Figure 1B , Suppl. Table 1 ). We 237 note that these key genes tend to be high-degree nodes in STRING-based molecular network 238
(Wilcoxon rank sum test p-value < 9.6e-14, see Methods). We also found that some (10 of 481) 239 compounds were significantly correlated (Pearson correlation p-value < 0.0001 after Bonferroni 240 correction) with more than 3,200 genes ( Figure 1C ). Five of these ten compounds are 241 chemotherapeutic agents (Suppl. Table 2 ). In contrast, about 100 compounds were not 242 significantly correlated with any genes; these compounds are mostly probes that either lack 243 FDA approval or are not clinically used. The large disparity among the examined compounds in 244 terms of the number of correlated genes reflects the diversity of these 481 small molecules. 245
While many of them are chemotherapeutic, which can affect the expression of a large number of 246 genes, some compounds may be targeting specific mutations, post-translational modifications, 247 or protein expression. A closer examination revealed that the compounds with the highest 248 cytotoxicity had the fewest gene correlations (i.e., fewest genes whose expression correlates 249 with cytotoxic response were mostly those with low cytotoxicity) (Suppl. Figure 1) . This 250 suggests that the strategy of identifying compound-associated genes by correlating basal gene 251 expression profiles with cytotoxicity is likely to be more effective for more potent compounds, for 252 which average response is stronger. Figure 1D (distribution 269 of the number of compounds that are significantly associated with each pathway) and Figure 1E  270 (distribution of the number of pathways significantly associated with each compound). Both 271 distributions revealed a long tail. For instance, while each pathway was associated with an 272 average of 18 compounds (of the 481 tested), there were 10 pathways that were associated 273 with over 150 compounds (Suppl . Table 3 ). Likewise, while each compound was associated 274
with an average of eight pathways, there were 12 compounds associated with over 25 pathways 275 (Suppl. In a similar vein, two genes will have similar representations if they belong to the same 293 pathway(s) and/or exhibit the same network neighbors. A gene and a pathway can also be 294 compared in the low-dimensional space, and will be deemed similar if the gene is in the 295 pathway and/or the gene is related by network to other genes of the pathway. DCA performs 296 network-based embedding without utilizing gene expression or chemical response data. Next, 297
PACER identifies RCGs as a fixed number of genes the expression of which shows the greatest 298 correlation with chemical response to a specific compound. Finally, it scores a pathway based 299 on the average cosine similarity between the vector representation of the pathway and those of 300 the RCGs. A pathway can thus be found to be associated with a compound if, in the network, 301 the pathway genes are closely related to the compound's RCGs; this association can be 302 discovered even if the pathway does not actually include the RCGs. We note that scores 303 assigned by PACER are not statistical significance scores and are meant only to rank pathways 304 for association with a given compound. Also, a negative score assigned to a compound-305 pathway pair does not imply a negative correlation between expression levels of pathway genes 306 and chemosensitivity. Rather, it only implies a lack of evidence for an association between the 307 compound-pathway pair. 308 309
The PACER association scores for all combinations of 481 compounds and 223 NCI signaling 310 pathways are shown in Figure 2B . Figure 2B also shows compounds clustered into different groups based on their associations 339 with pathways. We found that many compounds with similar structure were grouped together. 340
For example, teniposide and etoposide had a Tanimoto similarity score of 0.94 between their 341 SMILE specifications, which was substantially higher than the average Tanimoto similarity score 342 of 0.3716 for all pairs of drugs. They were clustered together in the same group ( Figure 2D , 343 also marked as a rectangle in Figure 2B ), which had seven compounds. This group is 344 associated with a set of similar pathways, including 'p53 pathway', 'Direct p53 effectors', 345 'Signaling mediated by p38-alpha and p38-beta', and 'Signaling mediated by p38-gamma and 346 p38-delta'. We found support in the literature in favor of some of these associations. For 347 example, a previous study reported that etoposide activates p38MAPK and can be used as a 348 new combined treatment approach when used with p38MAPK inhibitor SB203580 35 . To take 349 another example, temsirolimus and tacrolimus, which are both epipodophyllotoxins and inhibit 350 topoisomerase II, have a Tanimoto similarity score of 0.82, and are grouped closely in Figure  351 2B For a more systematic comparison between the two methods, we evaluated PACER based on a 364 database of known compound targets. We performed the evaluation under the assumption that 365 a pathway containing at least one known target is an associated pathway. Huang et al. used 366 and suggested this approach 16 . We used it here to evaluate PACER, the baseline method, as 367 well as a third method presented by Huang et al. 16 Although this third method was proposed to 368 detect association between pathways and drug clades, it can directly detect pathway-compound 369 associations. We implemented the method ourselves (see Methods) and included it in our 370 evaluations. We obtained the known targets for 246 compounds in our compound set from Rees 371 et al. 8 We then computed the AUROC of pathway predictions made by PACER for each 372 compound, and plotted this information alongside analogous information for the baseline 373 method and the method of Huang et al. 16 As shown in Figure 2E , PACER identified pathways 374 with higher AUROC compared to the other two methods. For example, PACER identified 375 pathways with an AUROC greater than 0.75 for 22 different compounds, while the baseline 376 method achieved this level of AUROC for only 7 compounds. Table 1 shows the 10 compounds  377 for which PACER achieved highest AUROC. We present a closer examination of PACER 378 predictions for two of these compounds: 'cyclophosphamide' (0.80 AUROC) and 'nsc23766' 379 (0.84 AUROC) in Table 2 and Table 3 , respectively. These tables also show the 380 complementarity between PACER predictions and those of the baseline method. 381 382
We note that the AUROC values reported here are likely to be underestimates, as there is 383 literature evidence for some of the reported pathways being associated with the compound, 384 even though the pathway does not include a known target (and is thus considered a false 385 positive in our AUROC estimate). For example, our method identified the 'Fanconi anemia 386 pathway' as being associated with compound 'cyclophosphamide' ( Table 2 ). The Fanconi 387 anemia pathway is one of the major DNA damage response pathways disrupted in breast 388 cancer 38 , and is known to play an important role in cancer treatment by DNA crosslinking agents 389 such as cyclophosphamide 39, 40 . PACER also identified 'EPO signaling pathway' to be 390 associated with cyclophosphamide. Cyclophosphamide treatment has been reported to affect 391 EPO receptor expression in murine erythropoiesis 41 . Although we found no existing study to 392 corroborate the PACER-predicted association between cyclophosphamide and the 'ATR 393 signaling pathway', the cyclophosphamide analogue, mafosfamide, has been reported to 394 activate the ATM/ATR-Chk1/Chk2 pathway 42 . In addition, the predicted association of 395 cyclophosphamide with 'Class I PI3K signaling events' is supported by reports of the compound 396 activating the PI3K/Akt/mTOR signaling pathway in the ovary 43 . 397 398
The Rac1-specific inhibitor nsc23766 was also identified by PACER as being associated with 399 several pathways that include a known target ( Tanimoto similarity is larger than 0.8. This threshold was used in previous work to indicate high 423
Tanimoto similarity 50 . For a given compound, we used PACER to rank other compounds 424 according to the Spearman correlation coefficient between their rankings of pathways, and 425 asked if this ranking was predictive of chemical structure similarity. For each compound, an 426 AUROC score was computed to measure this predictive ability. We repeated this evaluation 427 with the three different methods of ranking pathways for a compound: PACER, the baseline 428 method, and the method of Huang et al. Figure 2F shows the number of compounds for which 429 the AUROC is above a specified threshold, for each of the three methods. We found that 430 PACER achieves better performance in identifying compounds with similar chemical structure 431 based on similarity of pathway ranking. For example, 21 (of 42) compounds yielded an AUROC 432 greater than 0.8 when using PACER, compared to 10 compounds meeting the same criterion 433 when using the baseline method. As compounds with similar chemical structure tend to be 434 functionally similar, our results demonstrate that PACER can be used to identify similar 435 compounds by integrating prior network information into chemosensitivity data. 436 437
We also compared the associations predicted by the three methods to those identified from an 438 external data set. To this end, we mined the Library of Integrated Network-Based Cellular 439
Signatures (LINCS) L1000 data 23 , which reports genes differentially expressed upon treatment 440 of various cell lines with a compound. For each compound in our analysis that is also included 441 as a perturbagen in the L1000 compendium, we established a LINCS-based benchmark of 442 significantly associated pathways. This was based on a Fisher's exact test (p-value ≤ 0.05) 443 between pathway genes and the most differentially expressed genes from treatments with the 444 same compound (see Methods). We required this criterion to be met in at least one of the cell 445 lines for which data was available from LINCS. We then assessed the concordance between 446 this set of LINCS-based compound-pathway associations and those predicted by either method 447 presented above. We recognize that this is not an ideal benchmark: LINCS data points to genes 448 (and, indirectly, to pathways) that are differentially expressed in response to treatment, while 449 PACER and the compared methods base their pathway predictions on genes that have basal 450 expression levels across cell lines that correlate with chemical response. At the same time, we 451 expect the pathways affected by chemical treatment to also be, to an extent, involved in 452 interpersonal variation of chemosensitivity, making this a suitable evaluation procedure. This 453 was inspired by similar observations in cancer biology: genes and pathways disrupted in cancer 454 tissues overlap with genes and pathways whose mutation status in germline non-tumor samples 455 is informative about disease susceptibility and progression. 456 457
To test whether the significant pathways identified from LINCS data agree with the pathways 458 predicted by one of the methods being evaluated (based on chemical response variation in 459 CCLE cell lines), we counted the compounds for which the two sets of predicted pathways 460 overlapped significantly (Fisher's exact test p-value Figure 2G , the 461 PACER approach predicts pathways concordant with the corresponding LINCS-based 462 benchmark for more compounds, compared to the baseline method and that of Huang et al. 16 463 For instance, when the baseline method used an FDR threshold of 10% to designate significant 464 pathway associations for each drug, and the PACER method predicted the same number of 465 pathways, the latter's predictions were concordant with the LINCS-based benchmark for 110 of 466 the 481 compounds, a nearly two-fold improvement over the baseline method's predictions. Our 467 evaluations actually provide evidence for the above-mentioned possibility that pathways 468 predictive of drug sensitivity overlap with genes that mediate drug response. In fact, we found 469 86 compounds for which the pathways identified from basal expression correlations and the 470 pathways identified from LINCS signatures overlap with FDR < 5%. 471 472
After observing the substantial improvement of PACER, we then investigated whether the 473 performance of PACER is stable when only using experimental derived protein-protein 474 interactions as input. We found that the performance of PACER, as per the three evaluations 475 presented above, was stable when only using experimental derived protein-protein interactions 476 as input (Suppl. Figure 4- We see many opportunities to improve upon the basic concept of PACER in future work. First, 527 although the current PACER framework was developed in an unsupervised fashion, the scores 528 assigned to each pathway for the given gene set can be used as the feature and plugged into 529 off-the-shelf machine learning classifiers for compound-pathway association identification. 530 Second, although this study focused on chemosensitivity response, the PACER method is 531 broadly applicable to testing the association between two sets of genes according to their 532 proximity in the network. Finally, although we use gene expression data as the molecular profile 533 of each cell line, it might be interesting to test our method based on other molecular data such 534 as somatic mutations and copy number alterations. 535 536 537 538 of a subnet of purple branch cluster of compounds, marked by a rectangle in Figure 2B .
FIGURE LEGENDS
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Comparative evaluation of different methods for predicting compound-pathway associations. 556
The ground truth used here is the pathways that contain any known target gene of the 557 compound. (F 
